Twist Bioscience Corp. Hits New 52-Week High of $125.60

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 125.60 on August 10, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 149.71%, significantly outpacing the S&P 500's growth of 21.34% during the same period. As a small-cap player in the Pharmaceuticals & Biotechnology industry, Twist Bioscience has garnered attention for its innovative approaches and strategic positioning within the market. The company's market capitalization stands at USD 2,730 million, reflecting its growing influence in the sector. Despite being in a loss-making phase, indicated by a negative price-to-earnings ratio, the company continues to navigate its financial landscape with a debt-to-equity ratio of -0.41 and a return on equity of -16.79%. With no dividend yield currently offered, investors are closely monitoring the company's operational metrics and market dynamics as it continues to evolve in a competitive industry. The recent price movement highlights the stock's volatility and potential for growth, marking a noteworthy chapter in Twist Bioscience's journey.